Strict IGF-1 Control in Acromegaly

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 27, 2017

Primary Completion Date

May 7, 2020

Study Completion Date

May 7, 2020

Conditions
Acromegaly
Interventions
DRUG

Pegvisomant

Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.

Trial Locations (5)

T6G 2B7

University of Alberta Hospital, Edmonton

N6A4V2

St. Joseph Health Care London, London

K1H 7W9

The Ottawa Hospital, Ottawa

H4A 3J1

McGill University Health Centre, Montreal

G1V 4G2

Centre hospitalier universitaire de Québec-Université Laval, Québec

All Listed Sponsors
lead

Unity Health Toronto

OTHER

NCT02952885 - Strict IGF-1 Control in Acromegaly | Biotech Hunter | Biotech Hunter